0000000000280756
AUTHOR
Javier Diaz
Effects of cadmium exposure on the ultrastructure of hepatopancreatic cells of Thais haemastoma (gastropoda, prosobranchia)
Abstract Specific histopathological parameters have been proposed as good indicators of heavy-metal pollution. Hence the study of ultrastructural alterations in target organs from sentinel animals after heavy-metal exposure may provide a useful tool in understanding the cellular role in heavy-metal metabolism. The main purpose of this study was the determination of the ultrastructural changes in the different hepatopancreatic-cell types of Thais haemastoma after experimental exposure to cadmium. Specimens of this species from the Gulf of Valencia were exposed to sublethal doses of cadmium during a period of 96 h. The hepatopancreas was excised and prepared in a routine manner for electron m…
RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2
ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…
Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
AimsTo assess the impact of anticoagulant treatment on risk for stroke and all-cause mortality of patients with atrial fibrillation using real-world data (RWD).MethodsPatients with prevalent or incident atrial fibrillation were selected throughout a study period of 5 years. Stroke, transitory ischemic attack, hemorrhagic stroke, and all-cause mortality were identified in the claims of the electronic health records (EHRs). Subjects were classified according to the anticoagulant treatment in four groups: untreated, vitamin K antagonists (VKAs), New Oral Anticoagulants (NOACs), and antiplatelet (AP). Risk of events and protection with anticoagulant therapy were calculated by Cox proportional h…